Primary and secondary liver cancer
Conditions
Interventions
Sponsors
HwaMei Hospital, University of Chinese Academy of Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. A written consent was obtained from all patients before enrollment. 2. The patients aged 18 to 80 were eligible for the study if they had (primary and secondary) liver cancer. 3. The patients had no evidence of extrahepatic metastasis. 4. Other local therapies including surgery, radiofrequency ablation (RFA), and transcatheter arterial chemoembolization (TACE) were ineffective or not suitable/contraindicated. 5. Other key eligibility criteria included a Eastern Cooperative Oncology Group (ECOG) performance score 2 x 10^3/uL, neutrophil count >1000/uL, hemoglobin >9 g/dL, creatinine = 80x10^9/L.
Exclusion criteria
Exclusion criteria: 1. HIFU treatment for allergy or skin ulcer or laparotomy for 2 months; 2. Active malignant tumor within two years prior to participating in the clinical trial (excluding the tumor targeted in this study); But local tumors that have been treated can be grouped; 3. Previous HIFU treatment; 4. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events;tumor response; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;progression-free survival; | — |
Countries
China
Contacts
Public ContactTong Yang
HwaMei Hospital, University of Chinese Academy of Sciences
Outcome results
None listed